Literature DB >> 27840055

Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables.

Ellen E Lee1, Suzi Hong2, Averria Sirkin Martin1, Lisa T Eyler3, Dilip V Jeste4.   

Abstract

OBJECTIVE: Inflammation may play a role in the accelerated physical aging reported in schizophrenia, though biomarker findings and associations with demographic and clinical factors are inconsistent.
METHODS: In a cross-sectional, case-control design, 95 outpatients with schizophrenia (mean age ± SD: 48.1 ± 10.2 years) and 95 demographically comparable healthy comparison subjects (HCs) (mean age ± SD: 48.1 ± 12.1 years) were studied. Sociodemographic and clinical data were collected, and plasma levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interferon-γ (IFN-γ) were assayed. The authors compared cytokine levels, examined demographic and clinical associations, and adjusted for relevant variables with linear models.
RESULTS: Individuals with schizophrenia had higher levels of TNF-α and IL-6 but not IFN-γ than HCs. Age was not related to cytokine levels, and age relationships did not differ between diagnostic groups. Women had higher levels of IL-6. TNF-α and IL-6 levels were significantly correlated with depressive symptoms, and adjustment for depression reduced the group effect for both. Within the HCs, TNF-α levels were associated with physical comorbidity and body mass index. IL-6 levels were significantly correlated with body mass index and within schizophrenia patients, with worse mental and physical well-being. Accounting for physical morbidity and mental well-being reduced group differences in TNF-α and IL-6 levels, respectively. Worse positive symptoms were associated with higher IL-6 levels.
CONCLUSION: Higher TNF-α and IL-6 levels in schizophrenia patients were associated with depression, physical comorbidity, and mental well-being. Further longitudinal studies are warranted to assess inflammation as a potential treatment target for a subgroup of schizophrenia.
Copyright © 2017 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IFN-γ; IL-6; TNF-α; cytokines; inflammation; schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27840055      PMCID: PMC5164855          DOI: 10.1016/j.jagp.2016.09.009

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  114 in total

1.  Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia.

Authors:  J Kowalski; P Blada; K Kucia; A Madej; Z S Herman
Journal:  Schizophr Res       Date:  2001-07-01       Impact factor: 4.939

2.  Serum interferon in patients with psychosis.

Authors:  O T Preble; E F Torrey
Journal:  Am J Psychiatry       Date:  1985-10       Impact factor: 18.112

3.  Serum cytokine concentrations in patients with schizophrenia.

Authors:  I Baker; J Masserano; R J Wyatt
Journal:  Schizophr Res       Date:  1996-05       Impact factor: 4.939

4.  Production of cytokines in acute schizophrenic psychosis.

Authors:  M Rothermundt; V Arolt; C Weitzsch; D Eckhoff; H Kirchner
Journal:  Biol Psychiatry       Date:  1996-12-15       Impact factor: 13.382

5.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

6.  Differential susceptibility of white matter tracts to inflammatory mediators in schizophrenia: an integrated DTI study.

Authors:  Konasale M Prasad; Catherine H Upton; Vishwajit L Nimgaonkar; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2014-10-22       Impact factor: 4.939

Review 7.  Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia.

Authors:  Dilip V Jeste; Owen M Wolkowitz; Barton W Palmer
Journal:  Schizophr Bull       Date:  2011-05       Impact factor: 9.306

8.  Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort.

Authors:  Y Morimoto; S M Conroy; N J Ollberding; Y Kim; U Lim; R V Cooney; A A Franke; L R Wilkens; B Y Hernandez; M T Goodman; B E Henderson; L N Kolonel; L Le Marchand; G Maskarinec
Journal:  Int J Obes (Lond)       Date:  2014-02-13       Impact factor: 5.095

9.  Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia.

Authors:  Bojana Dunjic-Kostic; Miroslava Jasovic-Gasic; Maja Ivkovic; Nevena V Radonjic; Maja Pantovic; Aleksandar Damjanovic; Sanja Totic Poznanovic; Aleksandar Jovanovic; Tatjana Nikolic; Natasa D Petronijevic
Journal:  Psychiatr Danub       Date:  2013-03       Impact factor: 1.063

10.  Cognitive impairment of executive function as a core symptom of schizophrenia.

Authors:  Thomas Wobrock; Ullrich K H Ecker; Harald Scherk; Thomas Schneider-Axmann; Peter Falkai; Oliver Gruber
Journal:  World J Biol Psychiatry       Date:  2009       Impact factor: 4.132

View more
  28 in total

1.  High prevalence and adverse health effects of loneliness in community-dwelling adults across the lifespan: role of wisdom as a protective factor.

Authors:  Ellen E Lee; Colin Depp; Barton W Palmer; Danielle Glorioso; Rebecca Daly; Jinyuan Liu; Xin M Tu; Ho-Cheol Kim; Peri Tarr; Yasunori Yamada; Dilip V Jeste
Journal:  Int Psychogeriatr       Date:  2019-10       Impact factor: 3.878

2.  Avoidance of accelerated aging in schizophrenia?: Clinical and biological characterization of an exceptionally high functioning individual.

Authors:  Barton W Palmer; Raeanne C Moore; Lisa T Eyler; Luz L Pinto; Elyn R Saks; Dilip V Jeste
Journal:  Schizophr Res       Date:  2017-08-08       Impact factor: 4.939

3.  Comparison of schizophrenia outpatients in residential care facilities with those living with someone: Study of mental and physical health, cognitive functioning, and biomarkers of aging.

Authors:  Ellen E Lee; Averria Sirkin Martin; Christopher N Kaufmann; Jinyuan Liu; Julie Kangas; Rebecca E Daly; Xin M Tu; Colin A Depp; Dilip V Jeste
Journal:  Psychiatry Res       Date:  2019-02-27       Impact factor: 3.222

4.  Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects.

Authors:  Tanya T Nguyen; Tomasz Kosciolek; Yadira Maldonado; Rebecca E Daly; Averria Sirkin Martin; Daniel McDonald; Rob Knight; Dilip V Jeste
Journal:  Schizophr Res       Date:  2018-09-26       Impact factor: 4.939

5.  Sleep Disturbances and Inflammatory Biomarkers in Schizophrenia: Focus on Sex Differences.

Authors:  Ellen E Lee; Sonia Ancoli-Israel; Lisa T Eyler; Xin M Tu; Barton W Palmer; Michael R Irwin; Dilip V Jeste
Journal:  Am J Geriatr Psychiatry       Date:  2018-10-11       Impact factor: 4.105

Review 6.  Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions.

Authors:  Tanya T Nguyen; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

7.  The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.

Authors:  Hussein Kadhem Al-Hakeim; Abbas F Almulla; Michael Maes
Journal:  Neurotox Res       Date:  2020-01-08       Impact factor: 3.911

8.  Childhood Adversity and Schizophrenia: The Protective Role of Resilience in Mental and Physical Health and Metabolic Markers.

Authors:  Ellen E Lee; Averria Sirkin Martin; Xin Tu; Barton W Palmer; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2018 May/Jun       Impact factor: 4.384

9.  A novel biomarker of cardiometabolic pathology in schizophrenia?

Authors:  Ellen E Lee; Dorothy D Sears; Jinyuan Liu; Hua Jin; Xin M Tu; Lisa T Eyler; Dilip V Jeste
Journal:  J Psychiatr Res       Date:  2019-06-18       Impact factor: 4.791

10.  DNA methylation age is not accelerated in brain or blood of subjects with schizophrenia.

Authors:  Brandon C McKinney; Huang Lin; Ying Ding; David A Lewis; Robert A Sweet
Journal:  Schizophr Res       Date:  2017-10-05       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.